ライフサイエンスコーパス: positron

1 emonstrate how detailed control of electron, positron and antiproton plasmas enables repeated formati

2 as the plasma response can be asymmetric for positrons and electrons.

3 terization and defect characterization using positron annihilation lifetime spectroscopy correlated w

4 to the vacancy VBi-O ''' as confirmed by the positron annihilation spectra.

5 The results are compared with data from positron annihilation spectroscopy (PAS), secondary ion

6 (64)Cu emits positrons as well as beta(-) particles and Auger and int

7 Production of dense positrons at GeV energies is very challenging since extr

8 lectrodynamics incorporated shows that a GeV positron beam with density of 2.5 x 10(22) cm(-3) and fl

9 Antihydrogen, a positron bound to an antiproton, is the simplest anti-at

10 volt of energy gain, accelerating a trailing positron bunch in a plasma is much more challenging as t

11 on of the energy gain by a distinct trailing positron bunch in a plasma wakefield accelerator, spanni

12 us mark the first acceleration of a distinct positron bunch in plasma-based particle accelerators.

13 A positron bunch is used to drive the plasma wake in the e

14 The unexpectedly high flux of cosmic-ray positrons detected at Earth may originate from nearby as

15 Visual assessment of amyloid positron emission tomographic (PET) images has been appr

16 y fluorine 18-labeled AV-1451 ([18F]AV-1451) positron emission tomographic (PET) imaging are linked w

17 n 11-labeled Pittsburgh Compound B (11C-PiB) positron emission tomographic (PET) imaging.

18 (11)C-(R)-rolipram positron emission tomographic (PET) scans were performed

19 Using [11C]DPA-713 positron emission tomographic data from 12 active or for

20 Investigations in humans have used positron emission tomographic metabolic and myocardial b

21 ere unchanged, and a fluorodeoxyglucose F 18 positron emission tomographic scan was normal.

22 computed tomography, and fluorodeoxyglucose positron emission tomographic scans revealed strikingly

23 This cross-sectional case-control positron emission tomographic study was performed in the

24 mmunology, human translational research, and positron emission tomographic vascular imaging.

25 ed in tumor xenografts by using small-animal positron emission tomographic/computed tomographic imagi

26 Eight patients with asthma completed positron emission tomographic/computed tomographic lung

27 d potentially have changed 332 of 1732 (19%) positron emission tomographies at low-risk physiological

28 s of 1344 pixel range of perfusion in paired positron emission tomographies.

29 n was assessed by MRI and fludeoxyglucose-18 positron emission tomography ((18)FDG-PET).

30 ion delivered to the liver utilizing an oral positron emission tomography (18) F-isotopologue validat

31 using fluorine-18-labeled fluorodeoxyglucose positron emission tomography ([(18)F]FDG PET), [(18)F]FD

32 Whole-body (18)F-fluodeoxyglucose positron emission tomography ([(18)F]FDG-PET) imaging ha

33 (18)F-Fluorodeoxyglucose-positron emission tomography (FDG-PET) has become a cent

34 t and high-resolution (18)fluorodeoxyglucose positron emission tomography (FDG-PET) imaging to unders

35 ce imaging (MRI) and (18)F-fluordeoxyglucose positron emission tomography (FDG-PET).

36 pir F 18 (previously known as AV 1451, T807) positron emission tomography (FTP-PET) imaging for tau a

37 We show that immuno-positron emission tomography (immuno-PET) can visualize

38 Positron emission tomography (PET) -computed tomography

39 Combined positron emission tomography (PET) and computed tomograp

40 single-photon emission tomography (SPECT) or positron emission tomography (PET) and coronary computed

41 hcare, Shanghai, China) followed by combined positron emission tomography (PET) and CT (hereafter, PE

42 (18)F-Fluorodeoxyglucose (FDG)-positron emission tomography (PET) and diffusion-weighte

43 y menstruating, asymptomatic women completed positron emission tomography (PET) and functional magnet

44 fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (PET) and hyperpolarized ca

45 h-resolution neuroimaging data consisting of positron emission tomography (PET) and magnetic resonanc

46 Nevertheless, studies using positron emission tomography (PET) and radioligands for

47 vity at fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) and survival in patie

48 22 healthy recreationally active males using positron emission tomography (PET) and the MOR-selective

49 is to synthesise current evidence on amyloid-positron emission tomography (PET) burden and presumed p

50 racy of fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) combined with diagnos

51 d mass spectrometric detection to quantify a positron emission tomography (PET) detection tracer for

52 fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (PET) has added value over

53 Dynamic positron emission tomography (PET) images were acquired

54 BACKGROUND AND Amyloid-positron emission tomography (PET) imaging (API) detects

55 Positron emission tomography (PET) imaging agents that d

56 Positron Emission Tomography (PET) imaging allows the es

57 ing (FL) and photodynamic therapy (PDT) with positron emission tomography (PET) imaging and internal

58 Amyloid positron emission tomography (PET) imaging is a valuable

59 exploited the potential targeting of TF for positron emission tomography (PET) imaging of pancreatic

60 Over the past years, positron emission tomography (PET) imaging studies have

61 Here we describe positron emission tomography (PET) imaging with (18)F-Ma

62 Positron emission tomography (PET) imaging with radiotra

63 ized male nonhuman primates (n = 3), we used positron emission tomography (PET) imaging with the radi

64 employed in the realm of nanoparticle-based positron emission tomography (PET) imaging, whereas its

65 g, or synthetic organic molecule for in vivo positron emission tomography (PET) imaging.

66 ased attenuation correction (ATAC) for brain positron emission tomography (PET) in an integrated time

67 Use of [(18)F]FDG-positron emission tomography (PET) in clinical breast ca

68 surgery on the human brain immune system by positron emission tomography (PET) in relation to blood

69 Positron emission tomography (PET) is a powerful analyti

70 Here, we show that positron emission tomography (PET) is advantageous for d

71 Positron emission tomography (PET) is an important drive

72 18-Fluorodeoxyglucose positron emission tomography (PET) is commonly utilized

73 tem (CNS) disorders, we sought to identify a positron emission tomography (PET) ligand to enable targ

74 ed that fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) may detect the inflam

75 tional magnetic resonance imaging (fMRI) and positron emission tomography (PET) multimodal imaging wi

76 DPGM) is developed for MR/photoacoustic (PA)/positron emission tomography (PET) multimodal imaging-gu

77 The method uses positron emission tomography (PET) of [(11)C]yohimbine b

78 Positron emission tomography (PET) offers superior contr

79 Here, we characterize a positron emission tomography (PET) probe for imaging DIP

80 by analyzing motor defects and binding of a positron emission tomography (PET) radioligand to the ve

81 ation is possible with the recent advance in positron emission tomography (PET) radioligands that bin

82 ch toward the radiosynthesis of heterocyclic positron emission tomography (PET) radioligands using th

83 Radiolabeling with long-lived positron emission tomography (PET) radionuclides, such a

84 (CCR2)-binding peptide adapted for use as a positron emission tomography (PET) radiotracer for nonin

85 While the benefits of MRI are many, positron emission tomography (PET) radiotracers are stil

86 A positron emission tomography (PET) scan confirmed the lu

87 Early response evaluation with positron emission tomography (PET) scan may improve sele

88 Ten subjects also completed a positron emission tomography (PET) scan to quantify DRN

89 nonsmokers participated in two [(11)C]ABP688 positron emission tomography (PET) scans on the same day

90 Previous positron emission tomography (PET) studies targeting the

91 ur objective was to determine the pattern of positron emission tomography (PET) tau tracer AV-1451 up

92 racer [(11)C]DAA1106 (a ligand for TSPO) and positron emission tomography (PET) to determine the effe

93 a radioligand that binds to the mGluR5, and positron emission tomography (PET) to quantify in vivo m

94 calisation and magnitude of the presumed tau Positron Emission Tomography (PET) tracer [(18)F]Flortau

95 Recent studies have shown that positron emission tomography (PET) tracer AV-1451 exhibi

96 Consequently, positron emission tomography (PET) tracers addressing tr

97 )-3 ([(11)C]-(R)-IPMICF16), a first-in-class positron emission tomography (PET) TrkB/C-targeting radi

98 duced D2R internalization can be imaged with positron emission tomography (PET) using D2R radiotracer

99 Positron emission tomography (PET) using radiolabeled li

100 ents of the New York metropolitan area using Positron Emission Tomography (PET) with [(11)C]racloprid

101 Purpose To demonstrate that positron emission tomography (PET) with fluorine 18 ((18

102 d tumor cytopenia on repeat (68)Ga-DOTA-TATE positron emission tomography (PET) within 6 months, sugg

103 sease (PD) with 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET), and their associatio

104 Radiocaine, an F-18 radiotracer for positron emission tomography (PET), is the first SCN5A i

105 nitive continuum aged >60 years with amyloid positron emission tomography (PET), tau PET, and magneti

106 g a combination of functional MRI (fMRI) and positron emission tomography (PET), we investigated whet

107 ANCE STATEMENT: We present a high-resolution positron emission tomography (PET)- and magnetic resonan

108 In our phase 2 study of positron emission tomography (PET)-adapted salvage thera

109 stine, prednisone (R-CHOP14) induction and a positron emission tomography (PET)-driven ASCT or standa

110 yloid deposition, measured using florbetapir positron emission tomography (PET).

111 (sr39tk) reporter gene for cell detection by positron emission tomography (PET).

112 entual application in molecular imaging with positron emission tomography (PET).

113 , a dopamine D2/D3 receptor radiotracer, and positron emission tomography (PET).

114 -L1 VHH) to track PD-L1 expression by immuno-positron emission tomography (PET).

115 tion and whole-body dosimetry assessments by positron emission tomography (PET).

116 A positron emission tomography (PET)/ computed tomography

117 Purpose [(18)F]Sodium fluoride (NaF) positron emission tomography (PET)/computed tomography (

118 Purpose To assess the accuracy of staging positron emission tomography (PET)/computed tomography (

119 time using a combination of autoradiography, positron emission tomography (PET)/computed tomography (

120 eath hold (DIBH) in fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (

121 Purpose To develop a positron emission tomography (PET)/magnetic resonance (M

122 In this report, a case of fire in a positron emission tomography (PET)/magnetic resonance (M

123 Materials and Methods An integrated positron emission tomography (PET)/magnetic resonance (M

124 e of flourine 18 ((18)F) fluorocholine (FCH) positron emission tomography (PET)/magnetic resonance (M

125 correction (AC) (termed deep MRAC) in brain positron emission tomography (PET)/MR imaging.

126 arbon 11-labeled Pittsburgh Compound B (PiB) positron emission tomography after long-term prospective

127 3) or elevated (n = 202) brain amyloid using positron emission tomography amyloid imaging or a cerebr

128 inical evaluation and imaging at enrollment (positron emission tomography and 2-dimensional echo).

129 ers, and 18 nonsmokers who were scanned with positron emission tomography and [(11)C]raclopride, afte

130 14 healthy individuals using [(11)C]-acetate positron emission tomography and cardiovascular magnetic

131 disease, thanks to advances in MRI, amyloid positron emission tomography and cerebrospinal fluid bio

132 nt for pathogenesis and treatment.IMPORTANCE Positron emission tomography and computed tomography (PE

133 Positron emission tomography and computed tomography ima

134 essment in patients with lymphoma, including positron emission tomography and computed tomography sca

135 stic accuracy of Fluor-18-fluorodeoxyglucose positron emission tomography and computed tomography, la

136 MENT We here show that combined simultaneous positron emission tomography and magnetic resonance imag

137 d 77 years underwent 11C-(R)PK11195, 11C-PIB positron emission tomography and magnetic resonance imag

138 d the activity of the PSMA-PI3K axis through positron emission tomography and magnetic resonance imag

139 20 min, and 50 min with (15)O-water by using positron emission tomography and MRI.

140 A meta-analysis of 142 positron emission tomography and single photon emission

141 ects and 23 healthy controls participated in positron emission tomography and structural magnetic res

142 agnetic resonance imaging, amyloid (11C-PiB) positron emission tomography and tau (18F-AV-1451) posit

143 he results of their florbetapir F-18 (Abeta) positron emission tomography and their Alzheimer disease

144 ndication of neuroinflammation in vivo using positron emission tomography and TSPO-specific radioliga

145 ter stress testing with myocardial perfusion positron emission tomography and with left ventricular e

146 Staging used positron emission tomography and/or computed tomography.

147 ned by fluorodeoxyglucose F 18 [FDG]-labeled positron emission tomography and/or hippocampal volume [

148 beta-cells in pigs and nonhuman primates by positron emission tomography as well as in immunodeficie

149 amyloid-beta plaques measured as florbetapir positron emission tomography binding antecedent to 18F-A

150 dementia) and 12 healthy controls underwent positron emission tomography brain imaging with [(18)F]A

151 tomography, magnetic resonance imaging, and positron emission tomography can be used to assess pulmo

152 Positron emission tomography can be useful to identify a

153 cted by (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography computed tomography (PET/CT

154 Systemic venous sampling and positron emission tomography confirm uptake of glucose a

155 s an insufficient explanation of 18F-AV-1451 positron emission tomography data in vivo, at least in t

156 Fluorodopa positron emission tomography demonstrated significant in

157 and insulin sensitivity were measured using positron emission tomography during an isoglycemic clamp

158 ose concentrations) with 1-[(11)C]-d-glucose positron emission tomography during hyperinsulinemic glu

159 nts underwent magnetic resonance imaging and positron emission tomography for amyloid-beta ((11) C-Pi

160 healthy control subjects had 11C-(R)-PK11195 positron emission tomography for comparison.

161 New radioligands for positron emission tomography have generated considerable

162 Positron emission tomography image analysis was complete

163 aphy with iron oxide particles, and targeted positron emission tomography imaging are currently under

164 New recommendations for positron emission tomography imaging for the evaluation

165 nflammation, were measured with [(11)C]PBR28 positron emission tomography imaging in 15 healthy contr

166 Positron emission tomography imaging of mice bearing PC3

167 Positron emission tomography imaging reveals neuroinflam

168 We assessed the radiotracer 18F-AV-1451 with positron emission tomography imaging to compare the dist

169 had available plasma total tau levels, Abeta positron emission tomography imaging, and a complete neu

170 l and structural magnetic resonance imaging, positron emission tomography imaging, and behavioral dat

171 structural MRI, [(18)F]flutemetamol amyloid positron emission tomography imaging, apolipoprotein E g

172 d quantitative techniques, including in vivo positron emission tomography imaging, gamma counting, an

173 sessments, seizures, corticosteroid use, and positron emission tomography imaging.

174 onic uptake of [(18)F]-fluorodeoxyglucose by positron emission tomography in Hdc(-/-) mice.

175 etic resonance imaging and spectroscopy, and positron emission tomography in these areas and discusse

176 We suggest that 18F-AV-1451 positron emission tomography is a useful biomarker to as

177 Although, currently positron emission tomography is the most commonly used t

178 Here we compared binding of tau positron emission tomography ligands, PBB3 and AV-1451,

179 e in PCC fludeoxyglucose F 18 ([(18) F] FDG) positron emission tomography measured in Alzheimer's Dis

180 pleasant, and neutral images), and underwent positron emission tomography measurements of dopamine D2

181 latform for magnetic resonance/photoacoustic/positron emission tomography multimodal imaging and ligh

182 lume of denervated myocardium (defect of the positron emission tomography norepinephrine analog (11)C

183 [(11)C]5-hydroxy-tryptophan ([(11)C]5-HTP) positron emission tomography of the pancreas has been sh

184 For amyloid positron emission tomography positive (Abeta+) subjects,

185 Here, we report the development of a positron emission tomography probe for live bacterial in

186 D2/3 agonist positron emission tomography radiotracer [(11)C]N-propyl

187 id (defined by cerebrospinal fluid assays or positron emission tomography regional summaries) can be

188 ated variability; and (iii) this 18F-AV-1451 positron emission tomography retention pattern significa

189 We found that: (i) 18F-AV-1451 positron emission tomography retention was differentiall

190 ed with age, and cross-sectional florbetapir positron emission tomography retention, but not with yea

191 t increased annualized change in florbetapir positron emission tomography retention.

192 11C-(R)-PK11195 positron emission tomography reveals increased inflammat

193 Investigations at progression included positron emission tomography scan and biopsy.

194 dard for reporting the results of an amyloid positron emission tomography scan is to assign a dichoto

195 tently associated with an Abeta+ florbetapir positron emission tomography scan, not all Abeta+ subjec

196 = 306) and (18) fluorodeoxyglucose (n = 305) positron emission tomography scanning to assess amyloid

197 Positron emission tomography scanning with the transloca

198 F]fluoro-levo-dihydroxyphenylalanine dynamic positron emission tomography scans and striatal regions

199 resonance imaging and Pittsburgh compound B-positron emission tomography scans enrolled in the Mayo

200 3)I-MIBG scans, or [(18)F]fluorodeoxyglucose-positron emission tomography scans for MIBG-nonavid dise

201 eferred for rest/stress myocardial perfusion positron emission tomography scans from January 2006 to

202 ional resting-state (18)F-fluorodeoxyglucose positron emission tomography scans from VPA-exposed and

203 ne (MIBG) scans or [(18)F]fluorodeoxyglucose-positron emission tomography scans if the tumor is MIBG

204 atients were evaluated by fluorodeoxyglucose-positron emission tomography scans performed at baseline

205 DS AND In 127 volunteers, serial rest-stress positron emission tomography scans using rubidium-82 wit

206 D and 12 healthy controls (HC) completed two positron emission tomography scans with [(11)C]-(+)-PHNO

207 tomography binding antecedent to 18F-AV-1451 positron emission tomography scans, and to what extent t

208 betapir retention, antecedent to 18F-AV-1451 positron emission tomography scans, in the parieto-tempo

209 [(18)F]Fludeoxyglucose positron emission tomography showed increased myocardial

210 on between 18 kDa translocator protein brain positron emission tomography signal, which arises largel

211 years), response (PR v CR) after R-CHOP, and positron emission tomography status at assignment (negat

212 usion, this is one of the first longitudinal positron emission tomography studies evaluating longitud

213 Positron emission tomography studies report either no di

214 e disorder (MDD), highlighting insights from positron emission tomography studies.

215 study and invited these individuals back for positron emission tomography study with [(18)F]-fluorode

216 We used [(11)C](R)-PK11195 positron emission tomography to compare TSPO availabilit

217 ulti-session [(15)O]-water and [(18)F]-FDOPA positron emission tomography to determine striatal blood

218 fluorodihydroxyphenyl-l-alanine ([18F]-DOPA) positron emission tomography to examine dopamine synthes

219 Here we used positron emission tomography to investigate whether feed

220 hy age-matched control individuals underwent positron emission tomography to measure cerebral metabol

221 Here, we used [(11)C]NOP-1A and positron emission tomography to measure the in vivo bind

222 We used in vivo positron emission tomography to test whether feeding tri

223 labeled with fluorine-18 ((18)F) are used in positron emission tomography to visualize, characterize

224 n tau tangle accumulation (measured with the positron emission tomography tracer 18F-AV-1451) associa

225 The advent of tau-targeted positron emission tomography tracers such as flortaucipi

226 evelopment of tools such as radioligands and positron emission tomography tracers that are not curren

227 Using tau-specific and Abeta-specific positron emission tomography tracers, we show that in vi

228 brain amyloid burden, as detected by amyloid positron emission tomography using 11C-Pittsburgh B comp

229 ith [(11)C]carfentanil and [(18)F]fluorodopa positron emission tomography using a high-resolution sca

230 We acquired positron emission tomography using F18 flortaucipir (tau

231 1C-Pittsburgh compound B and 11C-(R)-PK11195 positron emission tomography was used to determine the a

232 [(18)F]CPFPX positron emission tomography was used to quantify A1AR a

233 on-human primates and in human studies using positron emission tomography were not consistent.

234 dy, flortaucipir tau and florbetapir amyloid positron emission tomography were obtained for 217 subje

235 Positron emission tomography with 18F-florbetapir and fl

236 f functional SGLT2 proteins in rodents using positron emission tomography with 4-[(18)F]fluoro-dapagl

237 (68)Gallium-DOTATATE positron emission tomography with computed tomography ((

238 t-Enhanced MRI (DCE-MRI) and Fludeoxyglucose Positron Emission Tomography(FDG-PET).

239 amyloid burden (measured by florbetapir F-18 positron emission tomography) and cognitive performance

240 ng cerebrospinal fluid (CSF) or imaging (tau positron emission tomography) biomarkers for Alzheimer d

241 etic resonance imaging, nuclear imaging, and positron emission tomography) performed on an outpatient

242 onal neuroimaging ([(18)F]fluorodeoxyglucose positron emission tomography) with a fear-regulating ext

243 trial (Prediction of Arrhythmic Events with Positron Emission Tomography).

244 on emission tomography and tau (18F-AV-1451) positron emission tomography, and episodic and semantic

245 ical assessment, brain 18-fluorodeoxyglucose positron emission tomography, electroneurography, and EL

246 ontribute to disease profiles of 18F-AV-1451 positron emission tomography, especially in primary tauo

247 erebral Abeta on Pittsburgh Compound B (PiB) positron emission tomography, gait speed over 4.57 m (15

248 Using positron emission tomography, magnetic resonance spectro

249 We used [(18)F]AV-1451 and [(11)C]PiB positron emission tomography, structural MRI, and neurop

250 nonoffenders were included and examined with positron emission tomography, using the radioligand [(11

251 glucose uptake, assessed through noninvasive positron emission tomography, was an effective predictiv

252 perfusion and coronary flow reserve (CFR) by positron emission tomography, where submaximal stress pr

253 Finally, the authors review positron emission tomography-based imaging techniques to

254 Positron emission tomography-based regional measures of

255 Purpose Magnetic resonance imaging (MRI) and positron emission tomography-computed tomography (PET-CT

256 ained from baseline (18)F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT

257 TV0 was measured by (18)F-fluorodeoxyglucose-positron emission tomography-computed tomography in 108

258 cation, adenocarcinoma histology, and higher positron emission tomography-computed tomography N stage

259 r extracranial metastatic lesions on choline positron emission tomography-computed tomography, and se

260 Vascular inflammation was assessed with positron emission tomography-computed tomography.

261 the clinical use of RHL30 in the context of positron emission tomography-guided response assessment

262 n were measured using 18F-fluorodeoxyglucose positron emission tomography.

263 scular magnetic resonance, and (11)C-acetate positron emission tomography.

264 e to that achieved by expert assessment with positron emission tomography.

265 ostic index, and CFR was quantified by using positron emission tomography.

266 [(18)F]fluorodeoxyglucose ([(18)F]FDG) with positron emission tomography.

267 in the murine brain for up to one week using positron emission tomography.

268 preparation of potential tracers for use in positron emission tomography.

269 new radiotracers for molecular imaging with positron emission tomography.

270 stenosis underwent (18)F-fluorodeoxyglucose-positron emission tomography/computed tomographic imagin

271 med to determine whether 18F-fludeoxyglucose-positron emission tomography/computed tomography (FDG-PE

272 ng of surveillance [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PE

273 (18)F-Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT

274 ings from dual-energy spectral CT(DEsCT) and positron emission tomography/computed tomography (PET/CT

275 Previously, we demonstrated that positron emission tomography/computed tomography (PET/CT

276 ascular inflammation by 18fluorodeoxyglucose positron emission tomography/computed tomography in vivo

277 ned in a single hybrid imaging session using positron emission tomography/computed tomography or sing

278 rom 31 patients and results of early interim positron emission tomography/computed tomography scans i

279 ascular inflammation by 18fluorodeoxyglucose positron emission tomography/computed tomography, with g

280 -to-background ratio by 18fluorodeoxyglucose positron emission tomography/computed tomography.

281 ar inflammation led to the increasing use of positron emission tomography/computed tomography.

282 together to enable simultaneous tetramodal (positron emission tomography/fluorescence/Cerenkov lumin

283 Positron emission tomography/magnetic resonance imaging

284 New radiolabeled probes for positron-emission tomography (PET) are providing an ever

285 information that could be available from tau positron-emission tomography scans and its use to determ

286 metabolic response by 18F-fluorodeoxyglucose positron-emission tomography.

287 accomplished through radiolabeling with the positron emitter (89)Zr.

288 s and amide derivatives with the short-lived positron emitter carbon-11 (t1/2 = 20.4 min) in generall

289 imately 2 d after injection and imaging of a positron-emitting molecular imaging agent into the submu

290 etic acid (NODAGA) and radiolabeled with the positron-emitting radionuclide (64)Cu (half-life, 12.7 h

291 The positron-emitting radionuclide carbon-11 ((11)C, t1/2 =

292 At present, diagnostic accuracy with positron-emitting radionuclides is greater than 90%.

293 synthesis, to detect living bacteria using a positron-labeled D-amino acid.

294 ompeting backgrounds by employing low-energy positrons (<1.25 eV) to create valence-band holes by ann

295 We now aimed to evaluate the potential of positron lymphography to characterize the nodes with res

296 Positron lymphography using (18)F-FDG followed by Cerenk

297 Positron lymphography using (18)F-FDG was successfully p

298 for fusing magnetically active species with positron- or gamma-ray-emitting radionuclides.

299 or ultra-bright gamma-ray emission and dense positron production with lasers at intensity of 10(22-23

300 fore unlikely to be the origin of the excess positrons, which may have a more exotic origin.